BACKGROUND: Nonadherence to aromatase inhibitors (AIs) is common and increases risk of breast cancer (BC) recurrence. We analyzed factors associated with nonadherence among patients enrolled in S1105, a randomized trial of text messaging. METHODS: At enrollment, patients were required to have been on an adjuvant AI for at least 30 days and were asked about financial, medication, and demographic factors. They completed patient-reported outcomes (PROs) representing pain (Brief Pain Inventory), endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms), and beliefs about medications (Treatment Satisfaction Questionnaire for Medicine; Brief Medication Questionnaire). Our primary endpoint was AI nonadherence at 36 months, defined as urine AI metabolite assay of less than 10 ng/mL or no submitted specimen. We evaluated the association between individual baseline characteristics and nonadherence with logistic regression. A composite risk score reflecting the number of statistically significant baseline characteristics was examined. RESULTS: We analyzed data from 702 patients; median age was 60.9 years. Overall, 35.9% patients were nonadherent at 36 months. Younger patients (younger than age 65 years) were more nonadherent (38.8% vs 28.6%, odds ratio [OR] = 1.51, 95% confidence interval [CI] = 1.05 to 2.16; P = .02). Fourteen baseline PRO scales were each statistically significantly associated with nonadherence. In a composite risk model categorized into quartile levels, each increase in risk level was associated with a 46.5% increase in the odds of nonadherence (OR = 1.47, 95% CI =1.26 to 1.70; P < .001). The highest-risk patients were more than 3 times more likely to be nonadherent than the lowest-risk patients (OR = 3.14, 95% CI = 1.97 to 5.02; P < .001). CONCLUSIONS: The presence of multiple baseline PRO-specified risk factors was statistically significantly associated with AI nonadherence. The use of these assessments can help identify patients for targeted interventions to improve adherence.
BACKGROUND: Nonadherence to aromatase inhibitors (AIs) is common and increases risk of breast cancer (BC) recurrence. We analyzed factors associated with nonadherence among patients enrolled in S1105, a randomized trial of text messaging. METHODS: At enrollment, patients were required to have been on an adjuvant AI for at least 30 days and were asked about financial, medication, and demographic factors. They completed patient-reported outcomes (PROs) representing pain (Brief Pain Inventory), endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms), and beliefs about medications (Treatment Satisfaction Questionnaire for Medicine; Brief Medication Questionnaire). Our primary endpoint was AI nonadherence at 36 months, defined as urine AI metabolite assay of less than 10 ng/mL or no submitted specimen. We evaluated the association between individual baseline characteristics and nonadherence with logistic regression. A composite risk score reflecting the number of statistically significant baseline characteristics was examined. RESULTS: We analyzed data from 702 patients; median age was 60.9 years. Overall, 35.9% patients were nonadherent at 36 months. Younger patients (younger than age 65 years) were more nonadherent (38.8% vs 28.6%, odds ratio [OR] = 1.51, 95% confidence interval [CI] = 1.05 to 2.16; P = .02). Fourteen baseline PRO scales were each statistically significantly associated with nonadherence. In a composite risk model categorized into quartile levels, each increase in risk level was associated with a 46.5% increase in the odds of nonadherence (OR = 1.47, 95% CI =1.26 to 1.70; P < .001). The highest-risk patients were more than 3 times more likely to be nonadherent than the lowest-risk patients (OR = 3.14, 95% CI = 1.97 to 5.02; P < .001). CONCLUSIONS: The presence of multiple baseline PRO-specified risk factors was statistically significantly associated with AI nonadherence. The use of these assessments can help identify patients for targeted interventions to improve adherence.
Authors: Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: N Lynn Henry; Faouzi Azzouz; Zereunesay Desta; Lang Li; Anne T Nguyen; Suzanne Lemler; Jill Hayden; Karineh Tarpinian; Elizabeth Yakim; David A Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544
Authors: Kelley M Kidwell; Steven E Harte; Daniel F Hayes; Anna Maria Storniolo; Janet Carpenter; David A Flockhart; Vered Stearns; Daniel J Clauw; David A Williams; N Lynn Henry Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: Lynne I Wagner; Fengmin Zhao; Paul E Goss; Judith-Anne W Chapman; Lois E Shepherd; Timothy J Whelan; Bassam I Mattar; Jose A Bufill; William C Schultz; Irving E LaFrancis; Gauri G Nagargoje; Radhakrishna Vemuri; Daniel A Nikcevich; George W Sledge; David Cella Journal: Breast Cancer Res Treat Date: 2018-02-17 Impact factor: 4.872
Authors: Ann H Partridge; Andrea LaFountain; Erica Mayer; Brooke S Taylor; Eric Winer; Aviva Asnis-Alibozek Journal: J Clin Oncol Date: 2008-01-07 Impact factor: 44.544
Authors: Kannie Chim; Sharon X Xie; Carrie T Stricker; Qing S Li; Robert Gross; John T Farrar; Angela DeMichele; Jun J Mao Journal: BMC Cancer Date: 2013-09-03 Impact factor: 4.430
Authors: Mark J Atkinson; Anusha Sinha; Steven L Hass; Shoshana S Colman; Ritesh N Kumar; Meryl Brod; Clayton R Rowland Journal: Health Qual Life Outcomes Date: 2004-02-26 Impact factor: 3.186
Authors: Sofia F Garcia; Robert J Gray; Joseph A Sparano; Amye J Tevaarwerk; Ruth C Carlos; Betina Yanez; Ilana F Gareen; Timothy J Whelan; George W Sledge; David Cella; Lynne I Wagner Journal: Cancer Date: 2021-10-06 Impact factor: 6.860
Authors: Xin Hu; Mark S Walker; Edward Stepanski; Cameron M Kaplan; Michelle Y Martin; Gregory A Vidal; Lee S Schwartzberg; Ilana Graetz Journal: JAMA Netw Open Date: 2022-08-01